ArticleThorax2003
Polymorphisms in the beta2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers.
Article in Thorax, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 48 citations in OpenAlex.
- Lack of association between ADRB2 (Gln27Glu) variant with susceptibility, severity and salbutamol response in South Indian asthmatics.Scientific reports · 2026Article
- Preliminary evidence for a role of the adrenergic nervous system in generalized anxiety disorder.Scientific reports · 2017Article
- Analysis of ADRB2 (Arg16Gly) Gene Variant with Susceptibility, Pharmacogenetic Response and Disease Severity in South Indian Asthmatics.Inflammation · 2015Article
- Molecular Characterization and Expression Analysis of Adrenergic Receptor Beta 2 (ADRB2) Gene before and after Exercise in the Horse.Asian-Australasian journal of animal sciences · 2015Article
- Modest genetic influence on bronchodilator response: a study in healthy twins.Croatian medical journal · 2015Article
- Polymorphisms of beta2-adrenergic receptor gene in serbian asthmatic adults: effects on response to Beta-agonists.Molecular diagnosis & therapy · 2014Article
- Genetic polymorphisms and asthma: findings from a case-control study in the Madeira island population.Biological research · 2014Article
- Methacholine PC20 in African Americans and whites with asthma with homozygous genotypes at ADRB2 codon 16.Pulmonary pharmacology & therapeutics · 2013Article
- Updates on the COPD gene list.International journal of chronic obstructive pulmonary disease · 2012Review
- Evaluation of spirometry values in relation to beta-2-adrenergic receptor gene polymorphism.European journal of medical research · 2010Article
- Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.Pharmacogenomics · 2010Review
- Traffic-related air pollution, oxidative stress genes, and asthma (ECHRS).Environmental health perspectives · 2009Article
- National Emphysema Treatment Trial state of the art: genetics of emphysema.Proceedings of the American Thoracic Society · 2008Review
- Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact of beta2-adrenergic receptor polymorphisms.BMC medicine · 2007Article
- Genetic predisposition to accelerated decline of lung function in COPD.International journal of chronic obstructive pulmonary disease · 2007Review
- Gene-environment interactions in asthma.Occupational and environmental medicine · 2006Review
- Beta2-adrenergic receptor polymorphisms are associated with asthma and COPD in adults.Journal of human genetics · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNon-specific bronchial hyperresponsiveness (NSBH) is a known predictor of accelerated rate of decline in lung function in smokers. Polymorphisms of the beta(2) adrenergic receptor (ADRB2) have previously been associated with NSBH and bronchodilator response (BDR) in asthmatics. Based on these associations, we hypothesised that ADRB2 polymorphisms would be associated with NSBH and BDR as well as an accelerated rate of decline in lung function among smokers.
methodsThe prevalence of two ADRB2 polymorphisms, Arg16-->Gly and Gln27-->Glu, was examined in 587 smokers chosen from the NHLBI Lung Health Study for having the fastest (n=282) and slowest (n=305) 5 year rate of decline in forced expiratory volume in 1 second (FEV(1); mean DeltaFEV(1) -4.14 and +1.08% predicted/year, respectively).
resultsContrary to our hypothesis, no ADRB2 allele or haplotype was associated with NSBH, BDR, or rate of decline in lung function. However, there was a significant negative association between heterozygosity at position 27 and a fast decline in lung function (adjusted odds ratio 0.56, 95% CI 0.40 to 0.78, p=0.0007).
conclusionsHeterozygosity at position 27 may be protective against an accelerated rate of decline in lung function. The polymorphism at position 16 does not contribute to the rate of decline in lung function, measures of NSBH, or BDR in smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.